NCT01230905

Study to Monitor the Effects of Androgen Suppression Treatment on the Heart

Does Androgen Suppression Treatment In Prostate Cancer Reduce Myocardial Blood Flow Reserve?

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 181 (actual)
• Sponsor: Ottawa Heart Institute Research Corporation · Academic / Other
• Sex: Male
• Age: 40 Years – 80 Years
• Healthy volunteers: Accepted

Summary

Suppression of effects of androgens with male sex hormones, androgen suppression treatment (AST), has been known to reduce deaths and prolong life in advanced prostate cancer. There have, however, been concerns raised in previous studies that androgen suppression may be associated with increased rate of heart attacks, particularly in older men. This study looks at prostate cancer patients in The Ottawa Hospital Cancer Clinic to see if treating these patients with androgen suppression is associated with a decrease in blood flow to the heart muscles by using Positron Emission Tomography (PET) and brachial artery ultrasound.

Detailed description

Treatment group: Prior to the initiation of AST, subjects will have a baseline N-13-ammonia PET scan and a brachial artery ultrasound at the University of Ottawa Heart Institute. Blood glucose and a lipid profile will be obtained. These tests will be repeated 6 - 9 months after starting AST. Cancer control group: The same testing and intervals will be performed. Normals control group: Baseline testing will be done to establish a normal.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
RADIATION	PET scan and ultrasound	Nuclear rest/stress testing of the heart using N-13-ammonia paired with brachial artery ultrasound

Timeline

• Start date: 2008-07-01
• Primary completion: 2011-09-01
• Completion: 2011-09-01
• First posted: 2010-10-29
• Last updated: 2017-04-24

Locations

1 site across 1 country: Canada